Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Much Will The Renin-Angiotensin-System (RAS)-Acting Agents Market Be Worth By 2029?

The market for agents that act on the renin-angiotensin-system (RAS) has witnessed consistent expansion in the recent past. Projections for growth indicate an increase from $5.82 billion in 2024 to $6.11 billion in 2025, with a compound annual growth rate (CAGR) of 5.0%. Several factors have spurred growth during the historic period, including a higher prevalence of hypertension, a rise in cardiovascular disease cases, an aging population, enhanced awareness about managing blood pressure, substantial support from clinical research, and approval of new drugs by regulatory bodies.

The market for agents targeting the renin-angiotensin-system (RAS) is forecasted to experience significant growth in the coming years, reaching a value of $7.55 billion by 2029, with a compound annual growth rate (CAGR) of 5.4%. Factors contributing to the projected growth include the increasing emphasis on individualized treatment strategies, amplified demand for fixed-dose combination therapy, escalated funding for cardiovascular research, enhanced health service accessibility in developing markets, and a rising incidence of lifestyle-associated diseases. Trends predicted to drive the market within this forecast timeframe involve the use of artificial intelligence in drug development, the incorporation of nanotechnology in drug delivery systems, advances in personalized medicine, using blockchain for the secure transfer of clinical data, the application of wearable biosensors for tracking hypertension, and the use of digital twin technology for creating patient models.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23496&type=smp

What External And Internal Drivers Are Influencing The Renin-Angiotensin-System (RAS)-Acting Agents Market?

The growth of the renin-angiotensin system (RAS)-acting agents market is anticipated to surge due to the amplified cases of hypertension. Hypertension, also known as high blood pressure, is a long-term health issue characterised by a persistently high force of blood applied to the artery walls. Factors such as unhealthy eating habits, especially the consumption of salt and processed foods, are contributing to the spike in hypertension cases, leading to an increased burden on the cardiovascular system. RAS-acting agents serve to mitigate the prevalence of hypertension by controlling blood pressure. This is achieved by inhibiting angiotensin II, a hormone that narrows blood vessels and promotes fluid retention, thereby facilitating vasodilation and decreasing blood pressure. As an example, the Australian Bureau of Statistics, a government agency in Australia, reported in October 2024 that 11.6% (3.0 million) of Australians suffered from hypertension in 2022, with the rates equally distributed among males (11.7%) and females (11.6%). Hence, the rising cases of hypertension provide impetus for the expansion of the renin-angiotensin system (RAS)-acting agents market.

How Is The Renin-Angiotensin-System (RAS)-Acting Agents Market Categorized Across Applications And Types?

The renin-angiotensin-system (ras)-acting agents market covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Renin Inhibitors, Aldosterone Antagonists, Other Drug Classes

2) By Indication: Hypertension, Heart Failure, Chronic Kidney Disease, Diabetic Nephropathy, Coronary Artery Disease

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics

4) By End-User: Hospitals, Research Institutes, Pharmaceutical Companies, Other End-Users

Subsegments:

1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril, Perindopril

2) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan, Olmesartan, Telmisartan

3) By Renin Inhibitors: Aliskiren

4) By Aldosterone Antagonists: Spironolactone, Eplerenone

5) By Other Drug Classes: Dual Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), Endothelin Receptor Antagonists, Vasopeptidase Inhibitors, Mineralocorticoid Receptor Antagonists (MRAs), Angiotensin Receptor Blockers With Neprilysin Inhibitors (ARNBIs)

How Are Market Trends Influencing Competition In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Leading firms in the market for renin-angiotensin system (RAS)-acting agents are dedicating their effort in the creation of advanced renin-angiotensin system (RAS) inhibitors, such as angiotensin-converting enzyme (ACE) inhibitors, in a bid to maximize effectiveness, reduce adverse reactions, boost patient adherence, and cater to conditions such as high blood pressure, heart failure, and renal diseases. An angiotensin-converting enzyme (ACE) inhibitor is a drug that suppresses blood pressure by impeding the enzyme that transforms angiotensin I into angiotensin II, a compound that tightens blood vessels. To demonstrate, in November 2023, Proveca Ltd. a pharmaceutical firm from the UK, was awarded a grant by the European Commission for pediatric use marketing authorization (PUMA) for Aqumeldi (enalapril maleate) orodispersible tablets, which are intended for addressing heart failure in children from birth up to 18 years of age. Aqumeldi is an angiotensin-converting enzyme (ACE) inhibitor that eases the conditions of pediatric heart failure patients by inhibiting the angiotensin-converting enzyme (ACE), blocking the transformation of angiotensin I into angiotensin II, consequently dilating blood vessels, enhancing blood circulation, and reducing heart strain.

Who Are The Most Influential Companies In The Renin-Angiotensin-System (RAS)-Acting Agents Market?

Major companies operating in the renin-angiotensin-system (RAS)-acting agents market are Pfizer Inc., Merck And Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, Sandoz International GmbH, Astellas Pharma Inc., Bausch Health Companies Inc., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Daiichi Sankyo Company Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/renin-angiotensin-system-ras-acting-agents-global-market-report

Which Region Holds The Greatest Opportunity For Renin-Angiotensin-System (RAS)-Acting Agents Market Expansion?

North America was the largest region in the renin-angiotensin-system (RAS)-acting agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the renin-angiotensin-system (RAS)-acting agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23496&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model